Atlas Trials

Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment

Clinical trial NCT04820023 · TERMINATED

Trial details

NCT number
NCT04820023
Sponsor
Bridge Biotherapeutics, Inc.
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
NSCLC
Start date
2021-04-02
Primary completion
2023-11-29
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.